- 503Pharma
- Posts
- BREAKING: FDA Pulls 12 Peptides from Category 2 List.
BREAKING: FDA Pulls 12 Peptides from Category 2 List.
Here's What Happens Next.
503Pharma .
April 15, 2026
The Regulatory Window Is Opening. Get Your Peptide Formulations Ready.
The 503Pharma Formula Library recently launched at app.503pharma.com. Ready-to-use formulations for sterile and non-sterile compounding, built to current USP 795/797 standards, with BUD assignments included. Updated as guidance changes.
90+ formulations across sterile and non-sterile categories
BUD assignments aligned to USP 795, 797 and 800
Custom formulation requests, if not in the library
Regularly updated as FDA and USP guidance evolves
The members area is free to join. Formula access is a paid feature.
Lead Story
Breaking — FDA / HHS / 503A Peptides
12 Peptides Coming Off Category 2: Kennedy Makes It Official
HHS Secretary Kennedy announced today that 12 peptide bulk drug substances are being removed from the FDA's Category 2 list. The FDA filed a Federal Register notice (Docket No. FDA-2025-N-6895) and updated the official 503A Categories page — both dated April 15, 2026. The FDA has already scheduled PCAC review dates for seven of the twelve (July 23–24). The remaining five go to PCAC by February 2027. This is the largest single batch of Category 2 removals since the list was created.
The Full List
Reference — Category 2 Removals
Which 12 Peptides Are Being Removed — And When FDA Will Review Them?
Substance | PCAC Review | Uses Evaluated |
|---|---|---|
BPC-157 (free base / acetate) | July 23, 2026 | Ulcerative colitis |
KPV (free base / acetate) | July 23, 2026 | Wound healing, inflammatory conditions |
TB-500 (Thymosin Beta-4 Fragment LKKTETQ) (free base / acetate) | July 23, 2026 | Wound healing |
MOTs-C (free base / acetate) | July 23, 2026 | Obesity, osteoporosis |
Emideltide (DSIP) (free base / acetate) | July 24, 2026 | Opioid withdrawal, chronic insomnia, narcolepsy |
Semax (heptapeptide) (free base / acetate) | July 24, 2026 | Cerebral ischemia, migraine, trigeminal neuralgia |
Epitalon (free base / acetate) | July 24, 2026 | Insomnia |
GHK-Cu (injectable routes) | By Feb 2027 | TBD |
Cathelicidin LL-37 | By Feb 2027 | TBD |
Dihexa Acetate | By Feb 2027 | TBD |
Melanotan II | By Feb 2027 | TBD |
PEG-MGF (Mechano Growth Factor, Pegylated) | By Feb 2027 | TBD |
What This Means
Analysis — For 503A Pharmacies
Category 2 Removal Is a Step — Not the Finish Line
Category 2 removal means these substances are no longer designated as presenting "significant safety risks." But it does not place them on Category 1, does not add them to the 503A Bulks List, and does not authorize compounding. The pathway runs through PCAC review, then notice-and-comment rulemaking. APC's Scott Brunner told the AP this will be a "protracted process."
After these removals, six substances remain on Category 2: Cesium Chloride, Domperidone, Germanium Sesquioxide, Ibutamoren Mesylate, Kisspeptin-10, and Quinacrine HCl (intrauterine). Ibutamoren and Kisspeptin-10 were already reviewed and rejected by PCAC in October 2024.
Key Dates
Timeline — What to Watch
Compliance Calendar
Date | Event |
|---|---|
April 22 | 12 peptides formally removed from Category 2 (seven days after April 15 notice) |
June 30 | Deadline to request oral presentation at PCAC. Contact Takyiah Stevenson ([email protected], 240-402-2507) |
July 9 | Deadline for public comments to be provided to PCAC members. Docket No. FDA-2025-N-6895 at regulations.gov |
July 22 | Docket closes |
July 23 | PCAC Day 1 — BPC-157, KPV, TB-500, MOTs-C. FDA White Oak Campus + virtual. Public sessions ~10:15am, ~11:50am, ~2:15pm, ~4:00pm ET |
July 24 | PCAC Day 2 — Emideltide (DSIP), Semax, Epitalon. Public sessions ~10:20am, ~12:30pm, ~3:20pm ET |
By Feb 2027 | PCAC review for GHK-Cu (injectable), LL-37, Dihexa, Melanotan II, PEG-MGF. Dates TBD |
Operator Playbook
Action Items — For 503A Pharmacies
What to Do Right Now
1. Start formulation development. Finalize MFRs, validate analytical methods, source APIs, establish stability protocols. Speed to market matters when authorization comes.
2. Submit public comments by July 9. Docket No. FDA-2025-N-6895 at regulations.gov. Comments go directly to PCAC members.
3. Monitor PCAC appointments. Vacancies exist. Panel composition will shape the outcome.
4. Get ahead of prescriber inquiries. Communicate the timeline and remaining steps before they start calling.
✉️ That’s your 503Pharma weekly digest. Our mission is to keep compounding professionals informed, prepared, and ahead of the curve.